Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
OpenAI Rejects Apple Trade Secret Theft Claims 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Milei Threatens Falkland Oil Firms With Sanctions 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Add as a preferred source on Google
SOUTH SAN FRANCISCO, Calif., March 06, 2018 -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that Bill Lis, chief executive officer, will present at the following conferences in March:
- Cowen and Company’s 38th Annual Health Care Conference on Tuesday, March 13, 2018, at 8:40 a.m. Eastern Time in Boston.
- Oppenheimer’s 28th Annual Healthcare Conference on Tuesday, March 20, 2018, at 10:55 a.m. Eastern Time in New York.
Both presentations will be webcast live and available for replay from Portola's website at www.portola.com in the Investor Relations section.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s first medicine Bevyxxa® (betrixaban), an oral, once-daily Factor Xa inhibitor, was approved by the U.S. Food and Drug Administration in June 2017. The company is also working to advance two clinical programs for andexanet alfa, a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a SYK/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective SYK inhibitors for inflammatory conditions. For more information, visit http://www.portola.com and follow the Company on Twitter @Portola_Pharma.
Investor Contact:
Cara Miller
Portola Pharmaceuticals
[email protected]
Media Contact:
Laurie Masonson
W2O Group
[email protected]
